Overview

A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

Status:
Completed
Trial end date:
2019-11-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of single dose intravenous rifampin on the single-dose PK of orally administered TAK-906.
Phase:
Phase 1
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Treatments:
Rifampin